NO20012981L - Bionedbrytbar polymerinnkapslet serotoninreseptorantagonist og fremgangsmate for fremstilling av samme - Google Patents

Bionedbrytbar polymerinnkapslet serotoninreseptorantagonist og fremgangsmate for fremstilling av samme

Info

Publication number
NO20012981L
NO20012981L NO20012981A NO20012981A NO20012981L NO 20012981 L NO20012981 L NO 20012981L NO 20012981 A NO20012981 A NO 20012981A NO 20012981 A NO20012981 A NO 20012981A NO 20012981 L NO20012981 L NO 20012981L
Authority
NO
Norway
Prior art keywords
compositions
active ingredient
biodegradable polymer
solid solution
useful
Prior art date
Application number
NO20012981A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012981D0 (no
Inventor
Rachel S Kohn
Stephen J Hanley
Stephen J Comiskey
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20012981D0 publication Critical patent/NO20012981D0/no
Publication of NO20012981L publication Critical patent/NO20012981L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
NO20012981A 1998-12-16 2001-06-15 Bionedbrytbar polymerinnkapslet serotoninreseptorantagonist og fremgangsmate for fremstilling av samme NO20012981L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21298698A 1998-12-16 1998-12-16
PCT/US1999/027705 WO2000035423A1 (en) 1998-12-16 1999-11-22 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same

Publications (2)

Publication Number Publication Date
NO20012981D0 NO20012981D0 (no) 2001-06-15
NO20012981L true NO20012981L (no) 2001-07-27

Family

ID=22793267

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012981A NO20012981L (no) 1998-12-16 2001-06-15 Bionedbrytbar polymerinnkapslet serotoninreseptorantagonist og fremgangsmate for fremstilling av samme

Country Status (35)

Country Link
EP (1) EP1140026B1 (bg)
JP (1) JP4759141B2 (bg)
KR (1) KR100707710B1 (bg)
CN (1) CN1195497C (bg)
AP (1) AP1769A (bg)
AR (1) AR021652A1 (bg)
AT (1) ATE303795T1 (bg)
AU (1) AU770673B2 (bg)
BG (1) BG65500B1 (bg)
BR (1) BR9916276A (bg)
CA (1) CA2355077C (bg)
CR (1) CR6424A (bg)
CZ (1) CZ301947B6 (bg)
DE (1) DE69927177T2 (bg)
DK (1) DK1140026T3 (bg)
EA (1) EA004502B1 (bg)
EE (1) EE200100314A (bg)
ES (1) ES2245128T3 (bg)
HK (1) HK1041645B (bg)
HR (1) HRP20010446A2 (bg)
HU (1) HU226586B1 (bg)
ID (1) ID28909A (bg)
IL (2) IL143761A0 (bg)
ME (2) MEP19408A (bg)
NO (1) NO20012981L (bg)
NZ (1) NZ511962A (bg)
OA (1) OA11728A (bg)
PL (1) PL196822B1 (bg)
RS (1) RS50123B (bg)
SK (1) SK285812B6 (bg)
TR (1) TR200101759T2 (bg)
TW (1) TWI221418B (bg)
UA (1) UA73101C2 (bg)
WO (1) WO2000035423A1 (bg)
ZA (1) ZA200104899B (bg)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10061932A1 (de) * 2000-12-13 2002-10-24 Pharmatech Gmbh Wirkstoffhaltige Mikropartikel und Verfahren zur Herstellung der Mikropartikel durch Abrasion
WO2002075273A2 (en) * 2001-03-20 2002-09-26 Euroscreen S.A. Screening, diagnostic and/or dosage method and device of an agonist and/or antagonist for a calcium-coupled receptor
US8501056B2 (en) * 2001-05-23 2013-08-06 Hexal Ag Homogenized product for implants and microparticles
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US8691277B2 (en) * 2004-09-21 2014-04-08 Shandong Luye Pharmaceutical Co., Ltd. Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009114648A1 (en) 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
BRPI0913724B8 (pt) * 2008-09-18 2021-05-25 Purdue Pharma Lp formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
WO2010151746A2 (en) * 2009-06-26 2010-12-29 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US20160193151A1 (en) * 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
EP4084607A4 (en) * 2019-12-31 2023-06-21 Wanka Tanka Ltd. EXTENDED RELEASE PLASTIC FORMULATION

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
CH679207A5 (bg) * 1989-07-28 1992-01-15 Debiopharm Sa
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
WO1991017772A1 (en) * 1990-05-16 1991-11-28 Southern Research Institute Controlled release dopamine and its use to stimulate nerve fiber growth
CA2083698C (en) * 1990-06-01 1997-11-04 Albert A. Carr (+)-alpha-(2,3-dimethoxyphenyl)-1- [2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
WO1992018106A1 (fr) * 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
US5505963A (en) * 1993-04-07 1996-04-09 Schwartz Pharma Ag Slow release pharmaceutical preparation
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法

Also Published As

Publication number Publication date
CR6424A (es) 2004-02-26
WO2000035423A9 (en) 2002-08-22
ME00066B (me) 2010-06-10
TR200101759T2 (tr) 2001-12-21
SK8282001A3 (en) 2001-11-06
DK1140026T3 (da) 2006-01-02
EA200100551A1 (ru) 2001-10-22
HUP0105048A3 (en) 2002-09-30
SK285812B6 (sk) 2007-08-02
ID28909A (id) 2001-07-12
WO2000035423A1 (en) 2000-06-22
AP2001002198A0 (en) 2001-09-30
EE200100314A (et) 2002-08-15
RS50123B (sr) 2009-03-25
KR20010082359A (ko) 2001-08-29
ATE303795T1 (de) 2005-09-15
CA2355077A1 (en) 2000-06-22
CZ301947B6 (cs) 2010-08-11
AU1742500A (en) 2000-07-03
AR021652A1 (es) 2002-07-31
NZ511962A (en) 2003-06-30
ES2245128T3 (es) 2005-12-16
CN1330536A (zh) 2002-01-09
BR9916276A (pt) 2001-09-04
HU226586B1 (en) 2009-04-28
IL143761A (en) 2006-08-01
AP1769A (en) 2007-08-22
TWI221418B (en) 2004-10-01
BG105591A (bg) 2002-01-31
JP4759141B2 (ja) 2011-08-31
KR100707710B1 (ko) 2007-04-18
EA004502B1 (ru) 2004-04-29
DE69927177D1 (de) 2005-10-13
HK1041645A1 (en) 2002-07-19
OA11728A (en) 2005-02-01
PL196822B1 (pl) 2008-02-29
JP2002532408A (ja) 2002-10-02
EP1140026B1 (en) 2005-09-07
YU41401A (sh) 2003-12-31
HUP0105048A2 (hu) 2002-05-29
CN1195497C (zh) 2005-04-06
NO20012981D0 (no) 2001-06-15
MEP19408A (en) 2010-06-10
DE69927177T2 (de) 2006-06-08
IL143761A0 (en) 2002-04-21
HK1041645B (zh) 2005-07-29
CA2355077C (en) 2009-05-26
UA73101C2 (en) 2005-06-15
HRP20010446A2 (en) 2002-06-30
ZA200104899B (en) 2002-09-16
BG65500B1 (bg) 2008-10-31
AU770673B2 (en) 2004-02-26
CZ20012157A3 (cs) 2001-09-12
PL348233A1 (en) 2002-05-20
EP1140026A1 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
NO20012981L (no) Bionedbrytbar polymerinnkapslet serotoninreseptorantagonist og fremgangsmate for fremstilling av samme
JP5599115B2 (ja) ２−オキソ−１−ピロリジン誘導体を含む医薬組成物
US20210212934A1 (en) Methods for providing long-lasting anesthetic effect using microparticles
CA2474698A1 (en) Polymer-based compositions for sustained release
JP6530845B2 (ja) イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物の安定化方法
CA2182593A1 (en) Oral liquid compositions containing paroxetine resinate
JP2004502729A (ja) Ｓｓｒｉおよびエストロゲン剤の組み合わせ
US10258605B2 (en) Use of indole compounds for fat reduction and skin and soft tissue tightening
DE202006018608U1 (de) Buprenorphin-Wafer zur Drogensubstitutionstherapie
NZ592339A (en) Solid pharmaceutical compositions of S1P receptor agonist with sugar alcohol
YU48766B (sh) Postupak za dobijanje farmaceutskog preparata za oralnu primenu sa usporenim oslobađanjem aktivne supstance bez rastvarača
NO20081325L (no) Nye doseringsformuleringer
WO2002003988A2 (en) Use of substituted indole compounds for treating neuropeptide y-related conditions
WO2006032202A1 (fr) Formulation à libération lente et prolongée contenant un agoniste du récepteur de la dopamine et son procédé de préparation
JPH10508029A (ja) 不安を治療する方法
JP2022548349A (ja) 医薬製剤
CA2345406A1 (en) Analgesic
US6369051B1 (en) Combinations of SSRI and estrogenic agents
CN1243540C (zh) 用于治疗阿尔茨海默氏型老年性痴呆的活性组分的组合
JP2003503459A (ja) パラセタモール及びブスピロンを含有した鎮痛性作用を有する新規医薬組成物
EA200100361A1 (ru) Сложные эфиры (+)-альфа-(2,3-диметоксифенил)-1-[2-(4-фторфенил)этил]-4-пиперидинметанола и их использование в качестве пролекарств антагониста mdl 110907 5htрецепторов
JP2001187737A (ja) 聴力改善剤
Álvarez‐Fuentes et al. Preclinical study of an oral controlled release naltrexone complex in mice
Jesudas et al. Formulation and evaluation of Escitalopram fast dissolving tablets by direct compression method
DE69923698D1 (de) Verwendung von 3-(1h-imidazol-4-ylmethyl)-indan-5-ol zur herstellung eines medikamentes zur intraspinalen, intrathekalen und epiduralen anwendung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application